Diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine - Boryung Pharmaceutical

Drug Profile

Diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine - Boryung Pharmaceutical

Alternative Names: BR 8002; BVN-002; DTaP-IPV combination vaccine

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 06 May 2016 Registered for Tetanus, Poliomyelitis, Pertussis and Diphtheria (In infants, Prevention) in South Korea (IM) (Boryung Pharmaceuticals pipeline, August 2016)
  • 01 Feb 2015 Phase-III clinical trials in Diphtheria (In infants, Prevention) in South Korea (IM) (NCT02458183)
  • 01 Feb 2015 Phase-III clinical trials in Pertussis (In infants, Prevention) in South Korea (IM) (NCT02458183)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top